Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Incyte buys Ariad’s European operations

by Rick Mullin
May 16, 2016 | A version of this story appeared in Volume 94, Issue 20

Incyte has agreed to acquire the European operations of the oncology drug firm Ariad Pharmaceuticals. In addition, Incyte will obtain an exclusive license to develop and commercialize the Ariad cancer drug Iclusig, a kinase inhibitor, in Europe and countries including Russia, Israel, and Switzerland. Incyte will pay Ariad $140 million plus sales royalties and as much as $135 million in development and regulatory milestone payments.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.